Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 143.30 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 Next > Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 March 30, 2023 Via Benzinga 3 Growth Stocks That Could Disrupt the Healthcare Industry March 13, 2023 These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. Via InvestorPlace Analyst Expectations for Neurocrine Biosciences's Future March 03, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 March 03, 2023 Via Benzinga Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets February 06, 2023 Neurocrine also topped fourth-quarter revenue expectations on Monday. Via Investor's Business Daily Earnings Scheduled For February 6, 2023 February 06, 2023 Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. Via Benzinga Five Best And Worst Performing Healthcare Stocks In January 2023 February 05, 2023 After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... Via Talk Markets Neurocrine Biosciences Earnings Preview February 03, 2023 Via Benzinga Why Voyager Therapeutics Stock Is Sinking This Week January 20, 2023 Investors are taking profits on this red-hot stock this week. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 February 03, 2023 Via Benzinga Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' February 03, 2023 Via Benzinga 7 A-Rated Stocks to Buy for Less Than $25 January 24, 2023 These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market. Via InvestorPlace Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review January 13, 2023 Sharp Tesla price cuts and some notable earnings were in focus. Via Investor's Business Daily Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal January 09, 2023 Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today. Via InvestorPlace Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies January 09, 2023 Via Benzinga Have A Look At William Blair's Top Biotech Picks For 2023 December 25, 2022 William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. Via Benzinga Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally December 17, 2022 UnitedHealth is among medical stocks holding key support. Via Investor's Business Daily Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth December 07, 2022 Via Benzinga How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market November 23, 2022 Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. Via Benzinga Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm November 16, 2022 Neurodegenerative disorders could mean big bucks for some biotechs. Via Investor's Business Daily Heska To $165? Plus BTIG Cuts PT On This Stock By 67% November 14, 2022 BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... Via Benzinga Stocks That Hit 52-Week Lows On Thursday December 01, 2022 During Thursday's session, 108 stocks hit new 52-week highs. Via Benzinga Looking Into Neurocrine Biosciences's Return On Capital Employed November 09, 2022 According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90... Via Benzinga Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review November 04, 2022 A mixed jobs report and heavy earnings swung stocks. Via Investor's Business Daily Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat November 01, 2022 The company raised its guidance for Ingrezza sales in 2022. Via Investor's Business Daily Neurocrine Biosciences: Q3 Earnings Insights November 01, 2022 Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 October 11, 2022 Upgrades Via Benzinga Earnings Scheduled For November 1, 2022 November 01, 2022 Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. Via Benzinga 3 Top Biotech Stocks Defying the Bear Market October 11, 2022 Bear market, shmear market. These biotech stocks are soaring despite the market downturn. Via The Motley Fool 4 Analysts Have This to Say About Neurocrine Biosciences September 26, 2022 Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.